Clinical implications of different risk factor profiles in patients with mesenteric venous thrombosis and systemic venous thromboembolism : a population-based study
(2019) In Journal of Thrombosis and Thrombolysis- Abstract
It is unknown whether the risk factor profile for mesenteric venous thrombosis (MVT) is different from systemic venous thromboembolism (VTE). The aim of the present population-based study was to compare acquired and inherited risk factors in MVT versus VTE. Identification of all MVT patients at Skåne University Hospital between 2000 and 2015 was performed in patient records and AuriculA (Swedish anticoagulation registry). VTE patients were retrieved from the Malmö Thrombophilia Study (MATS), including 1465 consecutive unselected VTE patients between 1998 and 2008. Patients with MVT (n = 120) were younger (p < 0.001), had higher glomerular filtration rate (p < 0.001), lower smoking rate (p < 0.001), and had less often undergone... (More)
It is unknown whether the risk factor profile for mesenteric venous thrombosis (MVT) is different from systemic venous thromboembolism (VTE). The aim of the present population-based study was to compare acquired and inherited risk factors in MVT versus VTE. Identification of all MVT patients at Skåne University Hospital between 2000 and 2015 was performed in patient records and AuriculA (Swedish anticoagulation registry). VTE patients were retrieved from the Malmö Thrombophilia Study (MATS), including 1465 consecutive unselected VTE patients between 1998 and 2008. Patients with MVT (n = 120) were younger (p < 0.001), had higher glomerular filtration rate (p < 0.001), lower smoking rate (p < 0.001), and had less often undergone recent surgery (p = 0.025). The prevalence of solid cancer (19.2% in MVT versus 12.1% in VTE; p = 0.026) and intra-abdominal cancer (16.7% versus 2.3%; p < 0.001) were higher in MVT. The prevalence of factor V Leiden mutation without presence of cancer was lower in MVT compared to VTE (26.6% versus 38.9%; p = 0.031). Thirty-day mortality was higher in the MVT group (9.2% versus 0.6%; p < 0.001), but did not differ at long-term follow-up according to Kaplan–Meier analysis (p = 0.73). Patients with MVT have a higher prevalence of cancer and lower prevalence of factor V Leiden mutation than those with systemic VTE. Intra-abdominal cancer should be excluded in MVT patients, and the high prevalence of factor V Leiden mutation in patients without cancer in both groups suggests that screening for thrombophilia in patients without cancer should be considered in this population for both groups.
(Less)
- author
- Salim, Saman LU ; Zarrouk, Moncef LU ; Elf, Johan LU ; Gottsäter, Anders LU ; Sveinsdottir, Signy LU ; Svensson, Peter LU and Acosta, Stefan LU
- organization
- publishing date
- 2019-02-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Factor V Leiden mutation, Mesenteric venous thrombosis, Prothrombin mutation, Thrombophilia testing, Venous thromboembolism
- in
- Journal of Thrombosis and Thrombolysis
- publisher
- Springer
- external identifiers
-
- scopus:85061489086
- pmid:30756343
- ISSN
- 0929-5305
- DOI
- 10.1007/s11239-019-01816-x
- language
- English
- LU publication?
- yes
- id
- 1abdc0b7-f671-40d2-b11f-e57a7c8f56ca
- date added to LUP
- 2019-02-21 13:16:30
- date last changed
- 2024-07-09 06:53:44
@article{1abdc0b7-f671-40d2-b11f-e57a7c8f56ca, abstract = {{<p>It is unknown whether the risk factor profile for mesenteric venous thrombosis (MVT) is different from systemic venous thromboembolism (VTE). The aim of the present population-based study was to compare acquired and inherited risk factors in MVT versus VTE. Identification of all MVT patients at Skåne University Hospital between 2000 and 2015 was performed in patient records and AuriculA (Swedish anticoagulation registry). VTE patients were retrieved from the Malmö Thrombophilia Study (MATS), including 1465 consecutive unselected VTE patients between 1998 and 2008. Patients with MVT (n = 120) were younger (p < 0.001), had higher glomerular filtration rate (p < 0.001), lower smoking rate (p < 0.001), and had less often undergone recent surgery (p = 0.025). The prevalence of solid cancer (19.2% in MVT versus 12.1% in VTE; p = 0.026) and intra-abdominal cancer (16.7% versus 2.3%; p < 0.001) were higher in MVT. The prevalence of factor V Leiden mutation without presence of cancer was lower in MVT compared to VTE (26.6% versus 38.9%; p = 0.031). Thirty-day mortality was higher in the MVT group (9.2% versus 0.6%; p < 0.001), but did not differ at long-term follow-up according to Kaplan–Meier analysis (p = 0.73). Patients with MVT have a higher prevalence of cancer and lower prevalence of factor V Leiden mutation than those with systemic VTE. Intra-abdominal cancer should be excluded in MVT patients, and the high prevalence of factor V Leiden mutation in patients without cancer in both groups suggests that screening for thrombophilia in patients without cancer should be considered in this population for both groups.</p>}}, author = {{Salim, Saman and Zarrouk, Moncef and Elf, Johan and Gottsäter, Anders and Sveinsdottir, Signy and Svensson, Peter and Acosta, Stefan}}, issn = {{0929-5305}}, keywords = {{Factor V Leiden mutation; Mesenteric venous thrombosis; Prothrombin mutation; Thrombophilia testing; Venous thromboembolism}}, language = {{eng}}, month = {{02}}, publisher = {{Springer}}, series = {{Journal of Thrombosis and Thrombolysis}}, title = {{Clinical implications of different risk factor profiles in patients with mesenteric venous thrombosis and systemic venous thromboembolism : a population-based study}}, url = {{http://dx.doi.org/10.1007/s11239-019-01816-x}}, doi = {{10.1007/s11239-019-01816-x}}, year = {{2019}}, }